Inhibikase Therapeutics (IKT) Return on Assets (2021 - 2024)
Historic Return on Assets for Inhibikase Therapeutics (IKT) over the last 5 years, with Q3 2025 value amounting to 0.15%.
- Inhibikase Therapeutics' Return on Assets rose 28900.0% to 0.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.15%, marking a year-over-year increase of 28900.0%. This contributed to the annual value of 0.51% for FY2024, which is 5100.0% up from last year.
- According to the latest figures from Q3 2025, Inhibikase Therapeutics' Return on Assets is 0.15%, which was up 28900.0% from 0.2% recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Return on Assets ranged from a high of 0.15% in Q3 2025 and a low of 3.04% during Q3 2024
- In the last 5 years, Inhibikase Therapeutics' Return on Assets had a median value of 0.56% in 2024 and averaged 0.78%.
- Per our database at Business Quant, Inhibikase Therapeutics' Return on Assets crashed by -20400bps in 2024 and then surged by 28900bps in 2025.
- Over the past 5 years, Inhibikase Therapeutics' Return on Assets (Quarter) stood at 0.33% in 2021, then tumbled by -102bps to 0.68% in 2022, then crashed by -83bps to 1.24% in 2023, then skyrocketed by 55bps to 0.56% in 2024, then soared by 72bps to 0.15% in 2025.
- Its last three reported values are 0.15% in Q3 2025, 0.2% for Q2 2025, and 0.25% during Q1 2025.